MA

Newbury Street Acquisition Corporation Announces Receipt of Nasdaq Letter

Retrieved on: 
Friday, May 3, 2024
Annual report, Security (finance), Form, Bank statement, Letter, Cryptocurrency

Boston, MA, May 03, 2024 (GLOBE NEWSWIRE) -- Newbury Street Acquisition Corporation (NASDAQ: NBST, the "Company") announced today that it received a letter dated April 24, 2024, from the Listing Qualifications Department The Nasdaq Stock Market LLC, indicating that the Company was not in compliance with Nasdaq listing rule 5250(c)(1), which requires the timely filing of all required periodic financial reports with the Securities and Exchange Commission.

Key Points: 
  • Boston, MA, May 03, 2024 (GLOBE NEWSWIRE) -- Newbury Street Acquisition Corporation (NASDAQ: NBST, the "Company") announced today that it received a letter dated April 24, 2024, from the Listing Qualifications Department The Nasdaq Stock Market LLC, indicating that the Company was not in compliance with Nasdaq listing rule 5250(c)(1), which requires the timely filing of all required periodic financial reports with the Securities and Exchange Commission.
  • The required filing in question is the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K").
  • The delay in filing the Form 10-K is related to the Company requiring additional time to finalize the financial statements for the fiscal year ended December 31, 2023, as referenced in the recent filing of Form 12b-25.
  • The Company expects to file the Form 10-K in the near future.

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
CNS, Central nervous system, Compensated emancipation, Employment

The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $55.16 per share, which is equal to the closing price of Praxis’ common stock on the Nasdaq Global Select Market on the date of grant.
  • The restricted stock units will vest in four equal annual installments, subject to each employee’s continued employment with Praxis on each vesting date.

Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

Retrieved on: 
Friday, May 3, 2024
Titan, Sale, Idiopathic pulmonary fibrosis, Prospectus, Aileron, ALRN, Security (finance), Form, Exercise, Patient, Fibrosis, S-3, Therapy

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.

Key Points: 
  • Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68.
  • The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aileron, and excluding any proceeds that may be received from exercise of the warrants.
  • Titan Partners Group, a division of American Capital Partners, acted as sole book-running manager for the offering.
  • The offering was made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement.

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Option, Elective surgery, Therapy, Employment, Pharmaceutical industry

The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Key Points: 
  • The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
  • Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
  • Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika.
  • The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

CPS Technologies to Participate in Sidoti Microcap Virtual Conference

Retrieved on: 
Friday, May 3, 2024
CPS, Webcast, Sidoti, Conference

NORTON, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that, as it did last year, the Company will participate in the Sidoti Microcap Virtual Conference on May 8 and 9, 2024.

Key Points: 
  • NORTON, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced that, as it did last year, the Company will participate in the Sidoti Microcap Virtual Conference on May 8 and 9, 2024.
  • A general presentation by management will be held at 9:15 a.m. Eastern on May 8, with one-on-one calls scheduled throughout the 8th and 9th; institutional investors are encouraged to contact Sidoti directly or CPS investor relations with any questions or to confirm a time to speak with management.
  • The general presentation will be webcast and will subsequently be made available on the Company’s website.
  • To watch the webcast live, please use this link: https://sidoti.zoom.us/webinar/register/WN_PPoWYJzjSPePoP6H5Q4kPA

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Cardiovascular disease, Therapy, Employment

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The employees received stock options to purchase an aggregate of 64,200 shares of the company’s common stock and an aggregate of 56,100 restricted stock units (RSUs).
  • The options have an exercise price of $6.01 per share, which is equal to the closing price of the company’s common stock on the date of grant.
  • The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Compensated emancipation, Employment

The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

Key Points: 
  • The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
  • The stock options have a ten-year term and an exercise price of $1.77 per share, which is equal to the closing price of Vor Bio’s common stock on May 1, 2024.
  • The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employee’s continued employment with Vor Bio on such vesting dates.
  • The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

Retrieved on: 
Friday, May 3, 2024
Diabetic retinopathy, Research, Quality of life, Eye, ARVO, OIS

BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May 5-9th) being held in Seattle, Washington.

Key Points: 
  • BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology Innovation Source (OIS) Retina 2024 (May 4th) and the Association for Research in Vision and Ophthalmology (ARVO) 2024 meetings (May 5-9th) being held in Seattle, Washington.
  • Presentations at OIS Retina 2024:

Rapid Micro Biosystems Reports First Quarter 2024 Financial Results

Retrieved on: 
Friday, May 3, 2024
Automation, Total, Investment, Growth, Video game

LOWELL, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Total revenue for the first quarter of 2024 increased 11% to $5.6 million compared to $5.0 million in the first quarter of 2023.
  • Total operating expenses were $12.8 million in the first quarter of 2024, compared to $13.1 million in the first quarter of 2023.
  • Net loss for the first quarter of 2024 was $13.3 million, compared to $13.9 million in the first quarter of 2023.
  • ET to discuss its first quarter 2024 financial results.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Therapy, Employment

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to one new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to one new employee to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Company’s compensation committee granted nonstatutory stock options to purchase up to an aggregate of 20,000 shares of the Company’s common stock to the one new employee on May 1, 2024, at an exercise price of $4.61 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on May 1, 2024.
  • The options have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee’s start date and 2.0833% of the shares underlying the option vesting monthly thereafter, subject to such employee’s continued service to the Company through the applicable vesting dates.